Deutsche Bank Reiterates Buy on Vertex Pharmaceuticals Following Press Release

Following the press release issued earlier Tuesday morning by Vertex Pharmaceuticals VRTX, Deutsche Bank analyst, Robyn Karnauskas reiterated the firm's Buy rating and $103.00 price target for Vertex shares. Karnauskas wrote, "Bottom line: We believe that this is the first step in Vertex platform treating entire cystic fibrosis population." Karnauskas based this on the belief that doctors will use the regimen for the high unmet need among the cystic fibrosis community for a viable treatment. For a more detailed look into the press release see Why Is Vertex Pharmaceuticals Up More Than 50 Percent?